Core Viewpoint - Investors suffering losses from Kyverna Therapeutics, Inc. are encouraged to participate in a class action lawsuit due to alleged securities fraud related to undisclosed adverse data from clinical trials [4][5]. Group 1: Class Action Details - The class period for the lawsuit begins from the February 2024 IPO [3]. - The deadline for lead plaintiffs to come forward is set for February 7, 2025 [3]. - Investors do not need to take any immediate action to be part of the class action; they can choose to retain counsel or remain absent [3]. Group 2: Allegations Against Kyverna - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials [5]. - It is claimed that the company withheld this adverse data, which misled investors regarding the company's business and operational prospects [5]. - The positive statements made by the company about its operations were allegedly materially misleading and lacked a reasonable basis [5].
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit